Swallow this, lose 9% in 6 months (no drugs involved)

Описание: A patient I call Harold had spent 20 years trying to lose weight, so we talked about a device you swallow instead of a drug.

In this video I use a composite patient to walk through the Epitomee capsule, a non-drug, swallowable weight loss device, and where it might fit for people who don't want or can't take GLP-1 medications. I go through the trial evidence honestly and compare it against what semaglutide and tirzepatide actually deliver.

— What you’ll learn —

• Why weight is a medical issue, not just willpower
• How the Epitomee capsule works and what it is trying to do
• What the RESET trial found: 56% lost at least 5% and 27% lost at least 10% of body weight at 24 weeks
• An honest look at GLP-1 drugs, including common side effects and the cardiovascular findings from SELECT
• How the device compares with semaglutide (STEP-1) and tirzepatide (SURMOUNT-1), and who it might suit

Subscribe if you want more honest medical breakdowns. This is general information based on one composite case, not personal medical advice, so speak to your own doctor about what's right for you.


— Chapters —

0:00 A twenty-year cycle, no drug
2:54 Is refusing a drug a variable?
4:30 A capsule that just takes up space
11:06 Patient-matched, not either/or


— Sources & references —

• Semaglutide obesity approval — diabetes 2017, obesity 2021 (FDA) — FDA drug approval records — Ozempic (Dec 5, 2017) & Wegovy (Jun 4, 2021)
https://www.fda.gov/media/185422/down...
https://www.drugs.com/history/ozempic...
https://www.drugs.com/history/wegovy....

• GLP-1 side effects: nausea, vomiting, GI disturbance common, often early — Bettge et al., Diabetes Obes Metab 2017; semaglutide SmPC/EMA; Wharton et al., DOM 2022 (STEP pooled)
https://pubmed.ncbi.nlm.nih.gov/27860...
https://pmc.ncbi.nlm.nih.gov/articles...
https://www.jci.org/articles/view/194740

• RESET trial — randomised, double-blind, placebo-controlled, n=279, 9 US centres, 6 months — Ard et al., Obesity (Silver Spring) 2025;33(3):500-511 (RESET, NCT04222322)
https://pubmed.ncbi.nlm.nih.gov/39904...
https://onlinelibrary.wiley.com/doi/f...
https://clinicaltrials.gov/study/NCT0...

• RESET (Epitomee capsule): 56% lost ≥5%, 27% lost ≥10% body weight at 24 wks (Ard et al., Obesity 2025) — Ard et al., Obesity 2025 (RESET trial, PMID 39904726)
https://pubmed.ncbi.nlm.nih.gov/39904...
https://www.nature.com/articles/s4136...
https://pmc.ncbi.nlm.nih.gov/articles...

• STEP-1: semaglutide ~15% weight loss at 68 weeks — Wilding et al., NEJM 2021;384:989-1002 (STEP 1 trial)
https://www.nejm.org/doi/full/10.1056...
https://www.acc.org/Latest-in-Cardiol...

• SURMOUNT-1: tirzepatide 20-22% weight loss at 72 weeks — Jastreboff et al., N Engl J Med 2022;387(3):205-216 (SURMOUNT-1)
https://pubmed.ncbi.nlm.nih.gov/35658...
https://www.nejm.org/doi/abs/10.1056/...

• SELECT trial — ~17,500 patients; semaglutide reduced major cardiovascular events — Lincoff et al., N Engl J Med 2023;389:2221-32 (SELECT trial)
https://www.nejm.org/doi/pdf/10.1056/...
https://pubmed.ncbi.nlm.nih.gov/37952...


— Important context —

This describes a single clinical observation, not a general treatment recommendation. On this — “Protocol: 2 capsules/day, 30 min before your two largest meals, each with 2 glasses of water” — the broader scientific evidence is currently mixed. Individual responses can differ from population-level results. Always discuss with your own clinician.

This describes a single clinical observation, not a general treatment recommendation. On this — “Early responders (≥2% by week 8) lost avg 9.3% by week 24, 11.2% at 48 weeks” — the broader scientific evidence is currently mixed. Individual responses can differ from population-level results. Always discuss with your own clinician.

This describes a single clinical observation, not a general treatment recommendation. On this — “ESSENCE trial — semaglutide improved liver histology (surrogate, not hard outcome)” — the broader scientific evidence is currently mixed. Individual responses can differ from population-level results. Always discuss with your own clinician.

This describes a single clinical observation, not a general treatment recommendation. On this — “STEP 9 — significant

Medical disclaimer: This video is for general information and education only. It is not medical advice and is not a substitute for a consultation with a qualified healthcare professional. Always seek the advice of your own doctor or another qualified clinician about any medical condition or before making any decision about your health. Never disregard professional medical advice, or delay seeking it, because of something you have watched here.